ArticleThe Journal of clinical psychiatry2011
Pharmacotherapy for late-life depression.
Article in The Journal of clinical psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Exercise for depression in older adults: a meta-analysis of randomized controlled trials adjusting for publication bias.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)Pooled it
- Treatment-Resistant Depression in Older Adults.The New England journal of medicine · 2024Review
- Research status and global trends of late-life depression from 2004 to 2023: bibliometric analysis.Frontiers in aging neuroscience · 2024Article
- Depression and Pseudodementia: Decoding the Intricate Bonds in an Italian Outpatient Setting.Brain sciences · 2023Article
- An Updated Analysis of Psychotropic Medicine Utilisation in Older People in New Zealand from 2005 to 2019.Drugs & aging · 2022Article
- A Case Study on Polypharmacy and Depression in a 75-Year-Old Woman with Visual Deficits and Charles Bonnet Syndrome.Geriatrics (Basel, Switzerland) · 2021Article
- Geriatric Depression and Inappropriate Medication: Benefits of Interprofessional Team Cooperation in Nursing Homes.International journal of environmental research and public health · 2021Article
- Focus on Depression in Parkinson's Disease: A Delphi Consensus of Experts in Psychiatry, Neurology, and Geriatrics.Parkinson's disease · 2021Article
- Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association.Frontiers in psychiatry · 2020Article
- Late-life depression: issues for the general practitioner.International journal of general medicine · 2018Review
- Antidepressant pharmacotherapy in old-age depression-a review and clinical approach.European journal of clinical pharmacology · 2017Review
- Approval of psychotherapy and medication for the treatment of mental disorders over the lifespan. An age period cohort analysis.Epidemiology and psychiatric sciences · 2017Article
- Digital Clock Drawing: differentiating "thinking" versus "doing" in younger and older adults with depression.Journal of the International Neuropsychological Society : JINS · 2014Article
- Pharmacologic treatment of depression in the elderly.Canadian family physician Medecin de famille canadien · 2014Review
- Use of atypical antipsychotics in the elderly: a clinical review.Clinical interventions in aging · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The 2001 expert consensus guidelines for treating major depressive disorder (MDD) in geriatric patients recommended antidepressant treatment in combination with psychotherapy. Recent evidence continues to support the use of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors as first-line agents in the elderly, and although the transdermal monoamine oxidase inhibitor selegilene has shown promise in adult patients, it has not been studied in geriatric depression. Augmentation therapy with atypical antipsychotics or other agents may provide benefits for agitated, psychotic, or resistant MDD in the elderly. The few treatment studies that have been conducted in the geriatric population since the publication of the guidelines have had mixed results and high placebo response rates. More large controlled trials are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.